Abstract
Current strategies for treatment and management of gliomas incorporate molecular markers to individualize patient care. Physiologic imaging identifies treatment-associated alterations in tissue properties including cellular viability, vascular function, and molecular response. Imaging biomarkers provide a noninvasive approach for early treatment response assessment and are an important tool to individualize patient management. Gliomas are heterogeneous tumors. Parametric response mapping (PRM) is a novel voxel-wise imaging analysis method which directly addresses the issue of tumor heterogeneity. PRM image analysis improves the predictive accuracy of imaging biomarkers in clinical applications including treatment response assessment. A multi-parametric imaging biomarker derived from MR perfusion and diffusion-weighted imaging (DWI) using a PRM analysis method provides early identification of high-grade glioma chemoradiation resistance. Further validation of PRM-derived imaging biomarkers is required prior to routine clinical application as an early treatment response marker.
Original language | English |
---|---|
Title of host publication | Glioma Imaging |
Subtitle of host publication | Physiologic, Metabolic, and Molecular Approaches |
Publisher | Springer International Publishing |
Pages | 109-126 |
Number of pages | 18 |
ISBN (Electronic) | 9783030273590 |
ISBN (Print) | 9783030273583 |
DOIs | |
State | Published - Jan 1 2019 |
Keywords
- Diffusion
- Glioma
- Magnetic resonance imaging (MRI)
- Parametric response map (PRM)
- Perfusion
- Quantitative response metric